Treatment of hemodialyzed patient with sunitinib.
Reckova
M
M
Kakalejcik
M
M
Beniak
J
J
D000740:Anemia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000601:surgery / Q000628:therapy*; D001026:Coronary Artery Bypass / Q000379:methods; D003967:Diarrhea / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009392:Nephrectomy; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D012074:Remission Induction / Q000379:methods; D006435:Renal Dialysis; D000077210:Sunitinib; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib